Diabetes Melitus Tipe 1

01Pathophysiology

Type 1 Diabetes Mellitus (T1DM) results from autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans within the pancreas. This process is primarily mediated by autoreactive CD4+ and CD8+ T lymphocytes that infiltrate the pancreatic islets, a histological finding known as insulitis. The autoimmune attack is strongly linked to genetic susceptibility conferred by the HLA class II genes on chromosome 6, particularly the HLA-DR3 and HLA-DR4 haplotypes. Environmental triggers such as viral infections (Coxsackie B virus, enteroviruses) or dietary factors are thought to initiate or accelerate the autoimmune cascade in genetically predisposed individuals, though the exact trigger remains incompletely understood.

The destruction of beta cells is gradual, and clinical symptoms only appear once approximately 80-90% of beta cell mass has been destroyed. This is a critical concept: there is a long preclinical phase during which autoantibodies are detectable but the patient remains euglycemic. Once the remaining beta cells can no longer produce sufficient insulin to maintain glucose homeostasis, the patient crosses the threshold into symptomatic hyperglycemia.

Insulin is an anabolic hormone. Its absence produces a catabolic state that directly explains every symptom. Without insulin, glucose cannot enter insulin-dependent tissues (muscle, adipose), leading to hyperglycemia. When blood glucose exceeds the renal threshold (approximately 180 mg/dL), glucose spills into the urine (glycosuria), pulling water with it via osmotic diuresis, producing polyuria. The resultant volume depletion triggers polydipsia. Because cells are starved of glucose despite its abundance in the blood, the hypothalamus drives hunger, causing polyphagia. Simultaneously, the body breaks down fat and protein for energy, leading to weight loss despite increased caloric intake. This paradox of "starving in the midst of plenty" is the hallmark of T1DM.

When insulin deficiency is severe, unopposed glucagon and counter-regulatory hormones (cortisol, epinephrine, growth hormone) accelerate lipolysis. Free fatty acids flood the liver and undergo beta-oxidation, producing ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone). Accumulation of these organic acids overwhelms the body's buffering capacity, resulting in a high anion gap metabolic acidosis known as diabetic ketoacidosis (DKA). The body compensates with rapid, deep breathing (Kussmaul respirations) to blow off $C{O}_{2}CO\_2$ and reduce acidity. The fruity odor on the breath is from exhaled acetone.

02Classification and Clinical Manifestation

Classification

By Stage

DKA Severity Classification

03Diagnostic Workup

In a classic exam vignette, a young, thin patient presenting with polyuria, polydipsia, weight loss, and a blood glucose of 350 mg/dL, the diagnosis is essentially clinical. A random plasma glucose $\ge \backslash geq$ 200 mg/dL in the presence of classic hyperglycemic symptoms is sufficient to diagnose diabetes in a single visit without repeat testing. This is the best initial diagnostic step when the presentation is acute and symptomatic.

When the presentation is ambiguous or the patient is asymptomatic, confirmation requires two abnormal results from the same or different tests (fasting glucose $\ge \backslash geq$ 126 mg/dL, HbA1c $\ge \backslash geq$ 6.5%, or OGTT 2-hour value $\ge \backslash geq$ 200 mg/dL) on separate occasions.

Once diabetes is confirmed, the next question on the exam is often: "Is this Type 1 or Type 2?" This is where autoantibodies and C-peptide become essential. Anti-GAD65 antibodies are the most commonly tested and the most sensitive single marker for T1DM autoimmunity. A positive result, combined with a low or undetectable C-peptide level (reflecting absent endogenous insulin production), confirms the diagnosis as Type 1. C-peptide is produced in equimolar amounts with insulin during proinsulin cleavage, so it serves as a reliable surrogate for endogenous insulin secretion that is not confounded by exogenous insulin administration.

In a patient presenting with DKA, the workup priorities shift to acute assessment. You must obtain: arterial blood gas (to confirm metabolic acidosis), basic metabolic panel (to calculate anion gap and check potassium), serum beta-hydroxybutyrate (preferred over urine ketones for accuracy), complete blood count, and urinalysis. The anion gap is calculated as:

$$AnionGap=N{a}^{+}-(C{l}^{-}+HC{O}_3^{-})Anion\backslash \; Gap\; =\; Na^+\; -\; (Cl^-\; +\; HCO\_3^-)$$

A normal anion gap is 8-12 mEq/L. In DKA, it is characteristically elevated due to accumulation of ketoacid anions.

A critical exam pearl: serum potassium may be initially normal or elevated in DKA despite total body potassium depletion. This is because acidosis and insulin deficiency both drive potassium out of cells into the extracellular space. Once insulin therapy begins and acidosis corrects, potassium shifts back intracellularly, and hypokalemia may become life-threatening if not anticipated and replaced.

04Management and Treatment

DKA Protocol

The management of DKA follows a strict, testable sequence: fluids first, then potassium assessment, then insulin.

Step 1: Aggressive IV fluid resuscitation with isotonic saline is the absolute first priority. Patients in DKA are profoundly volume-depleted (often 5-10% of body weight). Fluid replacement alone will begin to lower glucose by improving renal perfusion and glucosuria. Administer 0.9% NaCl at 15-20 mL/kg/hour for the first hour.

Step 2: Check serum potassium before starting insulin. This is one of the most commonly tested decision points. If potassium is below 3.3 mEq/L, insulin must be withheld and potassium aggressively replaced, because insulin will drive potassium further into cells and can precipitate fatal cardiac arrhythmias. If potassium is 3.3-5.3 mEq/L, add 20-40 mEq of KCl per liter of IV fluids and start insulin simultaneously. If potassium is above 5.3 mEq/L, start insulin and recheck potassium every 2 hours.

Step 3: Begin continuous IV regular insulin infusion at 0.1 units/kg/hour. The goal is a glucose reduction of 50-70 mg/dL per hour. When blood glucose drops to approximately 200 mg/dL, add dextrose (D5) to the IV fluids but continue the insulin drip. This is a frequently tested concept: you do not stop insulin when glucose normalizes because the goal of insulin in DKA is not merely to lower glucose but to suppress ketogenesis and close the anion gap. Stopping insulin prematurely will cause rebound ketoacidosis.

Transition to subcutaneous insulin occurs when the patient is eating, the anion gap has closed, pH is above 7.3, and bicarbonate is above 18 mEq/L. Overlap subcutaneous basal insulin with the IV drip for 1-2 hours before discontinuing the drip to prevent a gap in insulin coverage.

Basal-Bolus Regimen

All patients with T1DM require lifelong exogenous insulin. The standard regimen is basal-bolus therapy, which physiologically mimics normal insulin secretion:

Basal insulin (insulin glargine, given once daily, or insulin detemir, given once or twice daily) provides a steady background level of insulin over 24 hours, suppressing hepatic glucose output between meals and overnight. The total daily dose of insulin is typically estimated at 0.4-1.0 units/kg/day, with roughly 40-50% given as basal and 50-60% divided among pre-meal boluses.

Bolus insulin (rapid-acting: lispro, aspart, or glulisine) is administered 10-15 minutes before meals. The dose is calculated using two components: an insulin-to-carbohydrate ratio (e.g., 1 unit per 10-15 grams of carbohydrate) and a correction factor (e.g., 1 unit for every 50 mg/dL above target). Both ratios are individualized.

An alternative to multiple daily injections is a continuous subcutaneous insulin infusion (CSII) pump, which delivers rapid-acting insulin as both a continuous basal rate and patient-activated boluses.

HbA1c should be measured every 3 months, with a target of < 7% for most adults and an individualized target for children (often < 7.5%).

Screening for Complications

Because T1DM carries long-term microvascular and macrovascular risks, structured screening is essential. Diabetic retinopathy screening begins 5 years after diagnosis (or at the onset of puberty, whichever comes first) with annual dilated fundoscopic exams. Diabetic nephropathy screening begins at the same interval with annual urine albumin-to-creatinine ratio. If microalbuminuria is detected, first-line treatment is an ACE inhibitor or ARB, even in normotensive patients, due to the renoprotective effect. Patients should also be screened for thyroid disease (TSH) and celiac disease (tissue transglutaminase IgA antibodies) at diagnosis and periodically thereafter, given the high rates of autoimmune comorbidity.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on T1DM questions is by mismanaging the potassium in DKA. The classic trap: a patient presents with DKA, labs show a glucose of 500 mg/dL and a potassium of 3.0 mEq/L, and the question asks for the "next best step." The instinct is to start insulin, but the correct answer is to replace potassium first and withhold insulin. Administering insulin to a hypokalemic patient can cause fatal hypokalemia and cardiac arrest. This concept is tested repeatedly because it reverses the intuitive reflex to treat the hyperglycemia immediately.

A second common trap involves the transition point in DKA management. When glucose reaches 200 mg/dL, students frequently select "discontinue insulin drip" as the answer. The correct answer is to add dextrose to the IV fluids and continue the insulin infusion. The purpose of insulin in DKA is to halt ketogenesis. Stopping it prematurely will cause the anion gap to reopen even as glucose appears controlled.

Third, students often confuse T1DM with T2DM in atypical presentations. An overweight adolescent with acanthosis nigricans and new-onset diabetes is T2DM until proven otherwise, even though T1DM is "the diabetes of the young." Conversely, an adult over 30 presenting with what looks like T2DM but who is thin and poorly controlled on metformin should raise suspicion for LADA, and autoantibodies (especially anti-GAD65) should be checked.

Finally, remember that HbA1c can be falsely low or high depending on red blood cell turnover. Conditions that increase RBC turnover (hemolytic anemia, sickle cell disease, recent blood loss or transfusion) will falsely lower HbA1c, while conditions that decrease turnover (iron deficiency anemia, splenectomy) will falsely elevate it. This is tested as a reasoning question: "Why does this patient's HbA1c not match their home glucose readings?"

The core competency being tested across T1DM questions is the ability to recognize the autoimmune, insulin-deficient nature of the disease, to distinguish it from Type 2 and other forms of diabetes, and to execute the DKA management algorithm in the correct sequence with attention to potassium handling and the rationale for continuing insulin beyond glucose normalization.